FDA Approved Alzheimer's Drug to Reduce Metabolic Syndrome Markers
Alzheimer's medication can reduce inflammation and insulin resistance in patients with metabolic syndrome, according to a clinical trial by scientists at Northwell Health's Feinstein Institute for Medical Research. The findings could be a potential therapeutic intervention for metabolic syndrome, which affects 30 percent of the adults in the United States.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer